Andersons pediatric cardiology 2117
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (81.05 KB, 3 trang )
References
1.HinesRN.Theontogenyofdrugmetabolism
enzymesandimplicationsforadversedrug
events.PharmacolTher.2008;118(2):250–267.
2.NevilleKA,BeckerML,GoldmanJL,Kearns
GL.Developmentalpharmacogenomics.
PaediatrAnaesth.2011;21(3):255–265.
3.WagnerJ,LeederJS.Pediatric
pharmacogenomics:asystematicassessmentof
ontogenyandgeneticvariationtoguidethe
designofstatinstudiesinchildren.PediatrClin
NorthAm.2012;59(5):1017–1037.
4.LeederJS,BrownJT,SodenSE.Individualizing
theuseofmedicationsinchildren:making
goldilockshappy.ClinPharmacolTher.
2014;96(3):304–306.
5.WagnerJ,Abdel-RahmanSM.Pediatric
pharmacokinetics.PediatrRev.2013;34(6):258–
269.
6.RitschelW,KearnsGL.HandbookofBasic
Pharmacokinetics-IncludingClinical
Applications.7thed.AmericanPharmacist
Association:Washington,DC;2009.
7.RodriguezW,SelenA,AvantD,etal.
Improvingpediatricdosingthroughpediatric
initiatives:whatwehavelearned.Pediatrics.
2008;121(3):530–539.
8.LeederJS,KearnsGL,SpielbergSP,vanden
AnkerJ.Understandingtherelativerolesof
pharmacogeneticsandontogenyinpediatric
drugdevelopmentandregulatoryscience.JClin
Pharmacol.2010;50(12):1377–1387.
9.ZhouSF.Polymorphismofhumancytochrome
P4502d6anditsclinicalsignificance:partII.
ClinPharmacokinet.2009;48(12):761–804.
10.ZhouSF.Polymorphismofhumancytochrome
P4502d6anditsclinicalsignificance:partI.
ClinPharmacokinet.2009;48(11):689–723.
11.OhtsukiS,SchaeferO,KawakamiH,etal.
Simultaneousabsoluteproteinquantificationof
transporters,cytochromesp450,andUDPglucuronosyltransferasesasanovelapproachfor
thecharacterizationofindividualhumanliver:
comparisonwithmRNAlevelsandactivities.
DrugMetabDispos.2012;40(1):83–92.
12.ShimadaT,YamazakiH,MimuraM,InuiY,
GuengerichFP.Interindividualvariationsin
humanlivercytochromeP-450enzymes
involvedintheoxidationofdrugs,carcinogens
andtoxicchemicals:studieswithliver
microsomesof30Japaneseand30caucasians.J
PharmacolExpTher.1994;270(1):414–423.
13.HeZX,ChenXW,ZhouZW,ZhouSF.Impactof
physiological,pathologicalandenvironmental
factorsontheexpressionandactivityofhuman
cytochromeP4502d6andimplicationsin
precisionmedicine.DrugMetabRev.
2015;47(4):470–519.
14.KimuraS,UmenoM,SkodaRC,MeyerUA,
GonzalezFJ.Thehumandebrisoquine4hydroxylase(CYP2D)locus:sequenceand
identificationofthepolymorphicCYP2D6gene,
arelatedgene,andapseudogene.AmJHum
Genet.1989;45(6):889–904.
15.HeimMH,MeyerUA.Evolutionofahighly
polymorphichumancytochromeP450gene
cluster:CYP2D6.Genomics.1992;14(1):49–58.
16.GaedigkA.ComplexitiesofCYP2D6gene
analysisandinterpretation.IntRevPsychiatry.
2013;25(5):534–553.
17.ZangerUM,FischerJ,RaimundoS,etal.
Comprehensiveanalysisofthegeneticfactors
determiningexpressionandfunctionofhepatic
CYP2D6.Pharmacogenetics.2001;11(7):573–
585.
18.GaedigkA,SangkuhlK,Whirl-CarrilloM,Klein
T,LeederJS.PredictionofCYP2D6phenotype
fromgenotypeacrossworldpopulations.Genet
Med.2017;19(1):69–76.
